Trulicity (dulaglutide), superior to Victoza (liraglutide) in Japanese trial in type 2 diabetes-Eli Lilly

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg (dulaglutide) from Eli Lilly provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg (liraglutide)after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.

The study's primary objective was met, with Trulicity 0.75 mg demonstrating a greater A1C reduction from baseline compared to placebo at 26 weeks. At the final endpoint of 52 weeks, which is the focus of the data presentation at the meeting, Trulicity 0.75 mg demonstrated statistically greater A1C reductions compared to Victoza 0.9 mg, the highest approved dose in Japan (-1.39 percent vs. -1.19 percent). Additional results showed: Trulicity 0.75 mg provided statistically greater reductions in the average self-monitored blood glucose levels compared to Victoza 0.9 mg (-53.1 mg/dL vs. -46.8 mg/dL); and Trulicity 0.75 mg significantly lowered average post-meal blood glucose levels from baseline compared to Victoza 0.9 mg (-63.7 mg/dL vs. -55.4 mg/dL). Mean body weight did not change in either treatment group. Both Trulicity and Victoza were well-tolerated in the study. No cases of adjudicated pancreatitis were reported, and no new safety signals were seen.